INTRODUCTION {#s1}
============

Cancer is one of the most serious public health problems worldwide \[[@R1]\]. Intensive efforts have been undertaken to improve the efficacy of cancer diagnosis and therapy; however, the overall survival time of cancer patients is still short \[[@R2], [@R3]\]. Further studies on the risk factors, biomarkers, and therapeutic targets for cancer should reduce the cancer burden. Emerging evidence has revealed that genetic factors, such as single nucleotide polymorphisms (SNPs), influence cancer development, treatment efficacy, and survival time of cancer patients \[[@R2]\].

Mature microRNAs (miRNAs) are a class of endogenous, single-stranded, and non-protein-coding small RNAs, which play an important role in tumorigenesis and cancer progression \[[@R4]--[@R6]\]. The SNPs in the genomic miRNA sequences influence miRNA-dependent regulation and alter tumor susceptibility \[[@R7], [@R8]\].

The microRNA-34 (miR-34) family comprises three miRNAs, namely, miR-34a, miR-34b, and miR-34c \[[@R9]\]. The miR-34b/c gene rs4938723 has been associated with hepatocellular and colorectal cancer \[[@R10]--[@R12]\]. However, updated, recent meta-analyses of the rs4938723 association with cancer risk have been limited. In this study, we have systematically reviewed the published data, and integrated all published studies to evaluate the association between rs4938723 polymorphism and cancer risk.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Relevant studies from the PubMed, Embase, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases were examined. A flowchart of the selected studies is presented in Figure [1](#F1){ref-type="fig"}. In total, 304 studies were searched (288 from the databases and 16 using a manual search). 108 duplicated retrieval articles were excluded from this study. In addition, 158 records were excluded because of improper titles and/or abstracts. 38 eligible studies were selected for a detailed evaluation. From these, 16 articles were excluded from this study according to the inclusion and exclusion criteria. Finally, 22 original articles containing 23 studies were included in the meta-analysis \[[@R7], [@R13]--[@R33]\]. The characteristics of the studies included are listed in Table [1](#T1){ref-type="table"}. From the 23 studies, 20 were on patients of Asian descent, two were on patients of Caucasian descent, and one was on patients of African descent.

![Flow chart of studies selection in this meta-analysis](oncotarget-08-28888-g001){#F1}

###### Main characteristics of studies included in the meta-analysis

  Author      Year   Country   Ethnicity   Cancer type   Genotyping methods          Cases   Controls   Case   Control   P value for HWE test in our controls   Quality                                               
  ----------- ------ --------- ----------- ------------- --------------------------- ------- ---------- ------ --------- -------------------------------------- --------- ----- ----- ----- ----- ------ ----- ------ -----
  Hashemi-1   2016   Iran      Asian       PC            PCR-RFLP                    151     152        85     56        10                                     226       76    109   38    5     256    48    0.46   8
  Hashemi-2   2016   Iran      Asian       LL            PCR-RFLP                    110     120        77     31        2                                      185       35    62    52    6     176    64    0.24   5
  Sanaei      2016   Iran      Asian       BC            PCR-RFLP                    263     221        125    115       23                                     365       161   100   106   15    306    136   0.06   4
  Yuan        2016   China     Asian       CC            PCR-RFLP                    328     568        117    175       36                                     409       247   242   258   68    742    394   0.95   7.5
  Zhu         2015   China     Asian       ESCC          MALDI-TOF MS                237     274        113    99        25                                     325       149   122   122   30    366    182   0.95   8
  Chen        2015   China     Asian       PTC           PCR-RFLP                    784     1006       271    402       111                                    944       624   456   451   99    1363   649   0.41   8
  Pan         2015   China     Asian       GC            PCR-RFLP                    197     289        102    76        19                                     280       114   121   137   31    379    199   0.4    7.5
  Tong        2015   China     Asian       LL            Taqman assay                570     673        254    281       35                                     789       351   301   296   76    898    448   0.8    10
  Yang        2014   China     Asian       GC            PCR-RFLP                    419     402        193    186       40                                     572       266   156   184   62    496    308   0.53   7.5
  Zhang-1     2014   China     Asian       RCC           Taqman assay                710     760        302    324       84                                     928       492   352   344   64    1048   472   0.12   8.5
  Zhang-2     2014   China     Asian       ESCC          Taqman assay                1109    1275       489    536       84                                     1514      704   569   573   133   1711   839   0.52   10
  OH          2014   Korea     Asian       CRC           PCR-RFLP                    545     428        272    233       40                                     777       313   216   171   41    603    253   0.4    7
  Li          2013   China     Asian       NPC           PCR-RFLP                    217     360        82     104       31                                     268       166   168   155   37    491    229   0.89   9
  Han         2013   China     Asian       HCC           Fluorescent-probe qRT-PCR   1013    999        451    444       118                                    1346      680   456   424   119   1336   662   0.18   10
  Tian        2013   China     Asian       OS            Taqman assay                133     133        41     62        30                                     144       122   62    53    18    177    89    0.23   9
  Gao         2013   China     Asian       CRC           PCR-RFLP                    347     488        175    144       28                                     494       200   216   210   62    642    334   0.33   7.5
  Bensen-1    2013   America   African     BC            Genotyping array            742     658        362    317       63                                     1041      443   343   257   58    943    373   0.32   8
  Bensen-2    2013   America   Caucasian   BC            Genotyping array            1203    1088       496    563       144                                    1555      851   430   503   155   1363   813   0.69   8
  Yin         2013   China     Asian       ESCC          PCR-LDR                     629     686        277    278       45                                     832       368   310   290   73    910    436   0.68   9.5
  Son         2013   Korea     Asian       HCC           PCR-RFLP                    157     201        69     75        13                                     213       101   110   74    17    294    108   0.37   7
  Xu          2011   China     Asian       HCC           PCR-RFLP                    502     549        204    236       62                                     644       360   266   229   54    761    337   0.65   10
  Krzysztof   2011   Poland    Caucasian   LL            PCR-RFLP                    195     200        79     88        28                                     246       144   98    83    19    279    121   0.81   7
  You         2011   China     Asian       ESCC          MALDI-TOF MS                251     189        120    103       28                                     343       159   88    86    15    262    116   0.34   7

NPC nasopharyngeal carcinoma, PC prostate cancer, HCC hepatocellular carcinoma, OS osteosarcoma, CRC colorectal cancer, BC breast cancer, ESCC esophageal squamous cell cancer, LL lymphocytic leukemia, RCC renal cell cancer, CC cervical cancer, GC gastric cancer, PTC papillary thyroid carcinoma,

PCR-RFLP polymerase chain reaction--restriction fragment length polymorphism, PCR-LDR polymerase chain reaction--ligation detection reaction, MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

The 23 selected studies involved 10,812 cases and 11,719 controls. Among these studies, four studies were related to esophageal squamous cell cancer, three to hepatocellular cancer, three to breast cancer, three to lymphocytic leukemia, two to colorectal cancer, and two studies were related to gastric cancer. Only one study each was related to cervical cancer, papillary thyroid carcinoma, renal cell cancer, nasopharyngeal carcinoma, prostate cancer, and osteosarcoma. The genotype distribution in the controls was compatible with the Hardy--Weinberg equilibrium (HWE) in all 23 studies. The quality scores for the individual studies ranged from 4 to 10, and the median score was 8.0.

Main analysis results {#s2_2}
---------------------

In the meta-analysis of the 23 eligible studies, genotype CT was significantly associated with cancer susceptibility in the overall population (overdominant model CT versus CC/TT: P~H~ = 0.018, OR = 1.093, and 95% CI = 1.015--1.177), as shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. No association between rs4938723 polymorphism and cancer risk was observed in the allele, genotype, dominant, and recessive models.

###### ORs and 95% CI for cancer risk and pri-miR-34b/c polymorphism (rs4938723 T \> C) under different genetic models

  Comparison     Subgroup    *N*   Heterogeneity test   *Z* test*P~Z~*   Publication bias   OR and 95%CI                                  
  -------------- ----------- ----- -------------------- ---------------- ------------------ -------------- ------- ---------------------- ----------------------
  C vs. T        Overall     23    0                    75.7             0.356              0.492          0.677   1.031 (0.991--1.072)   1.041(0.956--1.134)
                 Asian       20    0                    77.2             0.470                                     1.037 (0.993--1.084)   1.037(0.940--1.143)
                 Caucasian   2     0.018                82.1             0.668                                     0.969 (0.867--1.084)   1.086 (0.746--1.580)
                 LL          3     0.002                83.9             0.571                                     0.929 (0.808--1.068)   0.886 (0.582--1.349)
                 ESCC        4     0.898                0                0.225                                     0.947 (0.867--1.034)   0.947 (0.867--1.034)
                 HCC         3     0.113                54.2             0.036                                     1.114 (1.007--1.233)   1.151 (0.974--1.360)
                 CRC         2     0.154                50.9             0.058                                     0.870 (0.754--1.005)   0.867 (0.706--1.066)
                 BC          3     0.304                16.1             0.556                                     0.973 (0.888--1.066)   0.978 (0.881--1.085)
                 GC          2     0.843                0                0.001                                     0.758 (0.643--0.893)   0.758 (0.643--0.893)
  CT vs. TT      Overall     23    0                    60.6             0.061              0.833          0.825   1.099 (1.040--1.162)   1.094 (0.996--1.203)
                 Asian       20    0                    64.1             0.118                                     1.107 (1.041--1.177)   1.091 (0.978--1.217)
                 Caucasian   2     0.192                41.2             0.853                                     1.015 (0.863--1.195)   1.061 (0.809--1.392)
                 LL          3     0.011                77.9             0.788                                     1.047 (0.865--1.267)   0.936 (0.578--1.515)
                 ESCC        4     0.599                0                0.552                                     1.038 (0.919--1.172)   1.038 (0.919--1.172)
                 HCC         3     0.121                52.6             0.016                                     1.191 (1.033--1.373)   1.250 (0.993--1.573)
                 CRC         2     0.222                32.9             0.741                                     0.967 (0.795--1.177)   0.964 (0.758--1.226)
                 BC          3     0.289                19.5             0.760                                     1.020 (0.897--1.161)   1.020 (0.878--1.185)
                 GC          2     0.381                0                0.018                                     0.755 (0.598--0.953)   0.755 (0.598--0.953)
  CC vs. TT      Overall     23    0                    72.1             0.794              0.460          0.622   0.994 (0.908--1.088)   1.025 (0.851--1.234)
                 Asian       20    0                    73.9             0.872                                     1.008 (0.911--1.115)   1.018 (0.822--1.261)
                 Caucasian   2     0.022                80.8             0.737                                     0.904 (0.710--1.151)   1.146 (0.517--2.539)
                 LL          3     0.005                81.3             0.568                                     0.745 (0.529--1.048)   0.744 (0.270--2.051)
                 ESCC        4     0.345                9.5              0.026                                     0.787 (0.638--0.972)   0.794 (0.632--0.998)
                 HCC         3     0.285                20.4             0.221                                     1.150 (0.919--1.439)   1.172 (0.895--1.535)
                 CRC         2     0.342                0                0.015                                     0.658 (0.470--0.923)   0.661 (0.471--0.928)
                 BC          3     0.386                0                0.300                                     0.897 (0.730--1.102)   0.896 (0.729--1.102)
                 GC          2     0.400                0                0.004                                     0.584 (0.405--0.842)   0.584 (0.405--0.842)
  CC/CT vs. TT   Overall     23    0                    70.9             0.145              0.792          0.890   1.078 (1.022--1.137)   1.081 (0.974--1.199)
                 Asian       20    0                    73.1             0.229                                     1.086 (1.024--1.152)   1.076 (0.955--1.213)
                 Caucasian   2     0.060                71.8             0.638                                     0.992 (0.850--1.157)   1.100 (0.738--1.640)
                 LL          3     0.005                81.5             0.688                                     0.986 (0.821--1.184)   0.902 (0.545--1.493)
                 ESCC        4     0.891                0                0.881                                     0.991 (0.882--1.113)   0.991 (0.882--1.113)
                 HCC         3     0.090                58.6             0.065                                     1.184 (1.034--1.354)   1.248 (0.987--1.577)
                 CRC         2     0.157                50               0.288                                     0.904 (0.750--1.089)   0.899 (0.690--1.171)
                 BC          3     0.287                19.9             0.958                                     0.997 (0.882--1.127)   0.999 (0.866--1.153)
                 GC          2     0.664                0                0.003                                     0.715 (0.574--0.892)   0.715 (0.574--0.892)
  CC vs. CT/TT   Overall     23    0                    64.0             0.704              0.561          0.557   0.946 (0.868--1.031)   0.970 (0.830--1.134)
                 Asian       20    0                    66.7             0.702                                     0.954 (0.867--1.050)   0.965 (0.806--1.157)
                 Caucasian   2     0.049                74.2             0.829                                     0.897 (0.716--1.124)   1.073 (0.564--2.043)
                 LL          3     0.008                79.2             0.521                                     0.703 (0.507--0.976)   0.739 (0.294--1.860)
                 ESCC        4     0.164                41.2             0.013                                     0.774 (0.633--0.947)   0.815 (0.612--1.086)
                 HCC         3     0.493                0                0.579                                     1.062 (0.859--1.314)   1.062 (0.859--1.314)
                 CRC         2     0.519                0                0.016                                     0.672 (0.485--0.930)   0.674 (0.486--0.934)
                 BC          3     0.387                0                0.241                                     0.890 (0.733--1.081)   0.889 (0.732--1.081)
                 GC          2     0.254                23.1             0.022                                     0.667 (0.471--0.943)   0.678 (0.452--1.017)
  CT vs.CC/TT    Overall     23    0.018                42.1             0.018              0.428          0.423   1.101 (1.044--1.161)   1.093 (1.015--1.177)
                 Asian       20    0.008                48.5             0.051                                     1.105 (1.042--1.172)   1.090 (1.000--1.189)
                 Caucasian   2     0.57                 0                0.597                                     1.042 (0.895--1.213)   1.042 (0.895--1.213)
                 LL          3     0.014                76.5             0.849                                     1.103 (0.919--1.325)   0.957 (0.611--1.501)
                 ESCC        4     0.303                17.6             0.190                                     1.081 (0.962--1.214)   1.067 (0.932--1.222)
                 HCC         3     0.195                38.9             0.035                                     1.157 (1.010--1.324)   1.192 (0.986--1.441)
                 CRC         2     0.357                0                0.729                                     1.034 (0.856--1.249)   1.034 (0.856--1.249)
                 BC          3     0.299                17.1             0.495                                     1.044 (0.923--1.179)   1.041 (0.950--1.197)
                 GC          2     0.193                41.1             0.140                                     0.847 (0.680--1.056)   0.833 (0.620--1.119)

*P~H~*: *P*-value of heterogeneity test; *P~Z~*: *P*-value of *Z* test; *P~B~*: *P*-value of Begg\'s test; *P~E~*: *P*-value of Egger\'s test; OR: odds ratio; 95% CI: 95% confidence interval; *N*: number of comparisons.

![Forest plots of the association between miR-34b/c gene rs4938723 and cancer susceptibility (overdominant model)](oncotarget-08-28888-g002){#F2}

Subgroup analysis results {#s2_3}
-------------------------

In Asian and Caucasian populations, no significant association was observed in any genetic models. For hepatocellular carcinoma, the rs4938723 polymorphism was associated with an increased cancer risk in the comparison model (allele C versus T: P~H~ = 0.113, OR = 1.114, and 95% CI = 1.007--1.233), genotype model (CT versus TT: P~H~ = 0.121, OR = 1.191, and 95% CI = 1.033--1.373), and overdominant model (CT vs. CC/TT: P~H~ = 0.195, OR = 1.157, and 95% CI = 1.010--1.324). For lymphocytic leukemia, no association was observed in any genetic models. The rs4938723 polymorphism decreased the risk for colorectal cancer in the genotype (CC vs. TT: P~H~ = 0.342, OR = 0.658, and 95% CI = 0.470--0.923) and recessive models (CC vs. CT/TT: P~H~ = 0.519, OR = 0.672, and 95% CI = 0.485--0.930). In addition, the rs4938723 polymorphism was negatively associated with gastric cancer risk in the comparison model of C versus T (P~H~ = 0.843, OR = 0.758, and 95% CI = 0.643--0.893), CT versus TT (P~H~ = 0.381, OR = 0.755, and 95% CI = 0.598--0.953), CC versus TT (P~H~ = 0.400, OR = 0.584, and 95% CI = 0.405--0.842), CC/CT versus TT (P~H~ = 0.664, OR = 0.715, and 95% CI = 0.574--0.892), and CC versus CT/TT (P~H~ = 0.254, OR = 0.667, and 95% CI = 0.471-0.943). The rs4938723 polymorphism showed also reverse correlation with esophageal squamous cell cancer in the comparison model of CC versus TT (P~H~ = 0.345, OR = 0.787, and 95% CI = 0.638--0.972) and CC versus CT/TT (P~H~ = 0.164, OR = 0.774, and 95% CI = 0.633--0.947).

Publication bias and sensitivity analysis {#s2_4}
-----------------------------------------

Begger\'s funnel plot and Egger\'s test were employed to evaluate the possible publication bias in our study. As shown in Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}, no evidence of publication bias was detected in all comparisons. Sensitivity analysis was performed to examine the influence of the individual data set to the pooled ORs. As shown in Figure [4](#F4){ref-type="fig"}, the pooled ORs and 95% CIs were not significantly altered when any part of the study was individually omitted. These data indicate that the results of our meta-analysis are reliable.

![Publication bias tested by Begg\'s funnel plot in general population\
Models represented in overdominant model.](oncotarget-08-28888-g003){#F3}

![Sensitivity analysis of each study included in this meta-analysis by omitting each data set in the meta-analysis (overdominant model)](oncotarget-08-28888-g004){#F4}

Cumulative meta-analysis {#s2_5}
------------------------

According to the chronological order of the cumulative analysis, OR point estimates and confidence intervals were stable and exhibited a good change of trend, as shown in Figure [5](#F5){ref-type="fig"}.

![Cumulative analysis according to the chronological order (overdominant model)](oncotarget-08-28888-g005){#F5}

DISCUSSION {#s3}
==========

The miR-34 family is largely considered a tumor suppressor miRNA \[[@R34], [@R35]\]. miR-34b/c is located on chromosome 11q23, and has tissue-specific functions and different expression patterns in various cancers \[[@R36]\]. The miR-34b/c gene rs4938723 polymorphism has been investigated because of its potential association with the increased risk for cancer development \[[@R13]--[@R15], [@R17]\]; however, the results remain inconclusive. This updated meta-analysis was performed to obtain conclusive results about the association of rs4938723 polymorphism and cancer risk. A total of 10,812 cancer cases and 11,719 healthy controls were retrieved for the analysis. An increased risk for cancer was observed for the rs4938723 polymorphism under overdominant (CT vs. CC/TT) model. A stratified analysis showed that this association was observed in people with hepatocellular carcinoma, colorectal cancer, gastric cancer, and esophageal squamous cell cancer. Our results indicate that the rs4938723 polymorphism is a risk factor for cancer.

Several meta-analyses investigated the association between miR-34b/c gene rs4938723 polymorphism and cancer risk \[[@R11], [@R12], [@R37]\]. In the study conducted by Qiu et al., the meta-analysis included 11 studies, and indicated that allele C and genotype CT might be risk factors for hepatocellular cancer, and protective factors for colorectal cancer \[[@R37]\]. The meta-analysis conducted by Li et al. included 13 studies, and indicated that the rs4938723 polymorphism was associated with an increased cancer susceptibility of the Asian population. However, the polymorphism reduced susceptibility to colorectal cancer and esophageal squamous cell cancer in Asians \[[@R11], [@R12]\].

Nine studies have been conducted from 2014 to 2016 \[[@R13]--[@R9], [@R32], [@R33]\]. These studies comprised 3,059 cases and 3,705 controls and were included in our current meta-analysis. Thus, our meta-analysis increased the number of relevant studies compared to previous meta-analyses. Our study had relatively large study number, thus we could conduct more subgroup analyses based on different ethnicities and types of cancer. The statistical power of our meta-analysis was significantly increased. Consistent with the previous meta-analyses, we observed an increased risk for cancer that was associated with the miR-34b/c gene rs4938723 polymorphism using the overdominant model.

Different cancer types might contribute differently to the overall result of our meta-analysis. In our analysis, 12 types of cancers were included. In the stratified analysis, the rs4938723 polymorphisms were associated with an increased risk of hepatocellular carcinoma, but with a decreased risk for colorectal, gastric, and esophageal squamous cell cancer.

Some limitations in this study should be mentioned: First, only studies in English and Chinese were included. Second, the number of included studies in some cancer types, such as gastric cancer, was relatively small. Nasopharyngeal carcinoma, osteosarcoma, renal cell cancer, cervical cancer, prostate cancer, and papillary thyroid carcinoma were each included only once, making stratification impossible. Therefore, the statistical power might be insufficient to assess the relationship in these cancers. Third, the studies included were mostly performed in the Asian population; two studies were in the Caucasian population, and one study was performed in the African population. Thus, large-scale studies including different cancer types and populations should be conducted in the future. Finally, some important confounding factors that contribute to cancer susceptibility, such as age, gender, and smoking, were not included in the stratified analysis and should be analyzed in future.

MATERIALS AND METHODS {#s4}
=====================

Searching and screening eligible studies {#s4_1}
----------------------------------------

In the present study, we conducted a comprehensive search of the PubMed, Embase, Web of Science, Wanfang, and CNKI databases to identify all potentially eligible studies on rs4938723 polymorphism and cancer risk. The last search was updated on December 22, 2016, by using the following search terms: (pre-mir-34b/c OR pri-miR-34b/c OR mir-34b/c OR microRNA-34b/c OR rs4938723), (gene OR polymorphism OR allele OR variation), and (cancer OR carcinoma OR tumor). We also manually searched the references of previous meta-analyses and reviews to identify other studies. All of the selected studies in our meta-analysis conformed to all of the following criteria: (1) case--control studies; (2) evaluation of rs4938723 polymorphism and cancer risk; (3) sufficient genotype frequency data for calculating the OR and 95% CI; and (4) genotype distribution of the control group that was consistent with the HWE. The major exclusion criteria were as follows: (1) duplicates of previous publications; (2) studies irrelevant to cancer or miRNA-SNPs; and (3) no available data used for the SNPs.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Two authors (HL and BXM) independently reviewed and determined whether an individual study was eligible for inclusion. A third reviewer would participate if any discrepancy was encountered, and a final decision was made by the majority of the votes. The following data were extracted from each eligible study: (1) the surname of the first author, (2) year of publication, (3) country, (4) ethnicity, (5) cancer type, (6) number of controls and cases, (7) allele or genotype frequencies of cases and controls, and (8) HWE of the control subjects. The quality assessment for each eligible study was assessed according to a methodological quality assessment scale that was extracted and modified from previous studies \[[@R38]\]. Six items were assessed. The quality scores ranged from 0 to 10.

Statistics {#s4_3}
----------

The strength of the association between rs4938723 polymorphism and cancer risk was assessed by ORs and corresponding 95% CIs under five different genetic models. The models were as follows: allele model (C vs. T), genotype model (CT vs. TT and CC vs. TT), dominant model (CC/CT vs. TT), recessive model (CC vs. CT/TT), and over-dominant model (CT vs. CC/TT). *p* \< 0.05 was considered statistically significant. We conducted subgroup analysis according to ethnicity and cancer type. Heterogeneity among studies was examined with Cochran\'s *Q* test and the *I*^2^ statistic \[[@R39]\]. A random-effect model was used if the *p value* of the heterogeneity tests was no more than 0.1 (*p* ≤ 0.1); otherwise, the fixed-effect model was used. Analysis was performed by using the STATA 11.0 (Stata Corporation, College Station, TX, USA).

CONCLUSIONS {#s5}
===========

In summary, our study shows that the miR-34b/c gene rs4938723 is a susceptible locus for cancer. The rs4938723 polymorphisms are associated with an increased risk for hepatocellular carcinoma, but decreased risk for colorectal, gastric, and esophageal squamous cell cancer.
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